for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Fresenius SE & Co KGaA

FREG.DE

Latest Trade

37.75EUR

Change

0.42(+1.13%)

Volume

610,421

Today's Range

37.32

 - 

37.97

52 Week Range

24.25

 - 

51.54

As of on the XETRA ∙ Minimum 15 minute delay

Pricing

Previous Close
37.33
Open
37.35
Volume
610,421
3M AVG Volume
45.12
Today's High
37.97
Today's Low
37.32
52 Week High
51.54
52 Week Low
24.25
Shares Out (MIL)
551.78
Market Cap (MIL)
20,812.32
Forward P/E
11.87
Dividend (Yield %)
2.25

Next Event

Full Year 2020 Fresenius SE & Co KGaA Earnings Release

Latest Developments

More

Fresenius Sees No Meaningful Pandemic Impact On Hospital Operations - Conference Call

Fresenius SE Q3 Net Income EUR 427 Million, Down 4%

Fresenius Nominates Wolfgang Kirsch To Become Chairman Of Supervisory Board

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Fresenius SE & Co KGaA

Fresenius SE & Co KGaA is a Germany-based healthcare group. It operates through four business segments. Fresenius Medical Care runs a global network of dialysis clinics, providing treatment for patients with chronic kidney failure. It also offers dialyzers, dialysis machines and renal pharmaceuticals. Fresenius Kabi specializes in intravenously administered generic drugs (IV drugs), clinical nutrition and infusion therapies. It also supplies hospitals with medical devices and products of transfusion technology. Fresenius Helios is a private hospital operator, with over 130 facilities in Germany, including maximum care hospitals and rehabilitation centers and, through Quironsalud, over 80 hospitals and outpatient centers, as well as approximately 300 Occupational Risk Prevention Centers in Spain. Fresenius Vamed manages projects and provides services for health care facilities worldwide, from development and turnkey construction to maintenance and total operational management.

Industry

Healthcare Facilities

Contact Info

Else-Kroener-Str. 1

61352

Germany

+49.6172.6080

https://www.fresenius.de/

Executive Leadership

Gerd Krick

Independent Chairman of the Supervisory Board

Stephan Sturm

Chairman of the Management Board, Chief Executive Officer

Michael Diekmann

Independent Deputy Chairman of the Supervisory Board

Niko Stumpfoegger

Independent Deputy Chairman of the Supervisory Board

Rachel Clare Empey

Chief Financial Officer, Member of the Management Board

Key Stats

1.96 mean rating - 24 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

33.9K

2018

33.5K

2019

35.4K

2020(E)

36.5K
EPS (EUR)

2017

3.250

2018

3.630

2019

3.440

2020(E)

3.196
Price To Earnings (TTM)
11.46
Price To Sales (TTM)
0.57
Price To Book (MRQ)
1.22
Price To Cash Flow (TTM)
3.75
Total Debt To Equity (MRQ)
160.77
LT Debt To Equity (MRQ)
137.67
Return on Investment (TTM)
6.91
Return on Equity (TTM)
4.51

Latest News

Latest News

Germany's Fresenius net income beats on strong dialysis, drugs units

German healthcare group Fresenius SE & Co <FREG.DE> third-quarter net income beat expectations on Thursday, buoyed by strong earnings at its dialysis unit, recovery in generic drugs and a rise in elective procedures at its hospitals.

Germany's Fresenius Q3 net income beats on strong earnings at dialysis, drugs units

German healthcare group Fresenius SE & Co beat third-quarter net income expectations on Thursday, buoyed by strong earnings at its dialysis unit, recovery in generic drugs and increased number elective procedures at its hospitals.

UPDATE 3-Fresenius cuts 2020 outlook on pandemic impact

* Shares down 4% (Adds details from conference call, updates shares)

BRIEF-Fresenius Appoints Sebastian Biedenkopf As Chief Legal And Compliance Officer

* SEBASTIAN BIEDENKOPF, CURRENTLY GENERAL COUNSEL OF ROBERT BOSCH GMBH, WILL JOIN THE MANAGEMENT BOARD OF FRESENIUS AS CHIEF LEGAL AND COMPLIANCE OFFICER

BRIEF-Fresenius Helios Acquires Hospital In Western Germany

* FRESENIUS HELIOS IS ACQUIRING THE MALTESER HOSPITAL (“MKHB”) IN THE WESTERN GERMAN CITY OF BONN

BRIEF-Fresenius Says FDA Accepted For Review Kabi's Biologics License Application For Biosimilar MSB11455

* FDA ACCEPTED FOR REVIEW COMPANY`S BIOLOGICS LICENSE APPLICATION (BLA) FOR MSB11455, A BIOSIMILAR CANDIDATE OF NEULASTA® (PEGFILGRASTIM) Source text for Eikon: Further company coverage: (Gdansk Newsroom)

BRIEF-Fresenius Says EMA Accepted Kabi's Submission For Pegfilgrastim Biosimilar For Review

* FRESENIUS KABI'S REGULATORY SUBMISSION FOR PEGFILGRASTIM BIOSIMILAR ACCEPTED FOR REVIEW BY EMA Further company coverage: (Berlin Speed Desk)

BRIEF-Fresenius CEO To FAZ: We Should Be Spared Major Financial Losses During Crisis

* FRESENIUS BOSS SEES WE WILL WEATHER CORONAVIRUS CRISIS WELL - FAZ NEWSPAPER

Fresenius reports Q1 net income beat on pandemic demand

Healthcare group Fresenius <FREG.DE> beat first-quarter net income expectations on Wednesday, citing a U.S. and European spike in demand for drugs and devices for COVID-19 patients and government help with costs incurred by health providers.

BRIEF-Fresenius Sees No Impact Of COVID-19 On Dividend Payments

* AKORN DAMAGES CLAIMS: EXPECTS DELAWARE COURT DECISION IMMINENTLY - CONF CALL

BRIEF-Fresenius Says Impact Of Covid-19 On Outlook Cannot Be Assessed

* IMPACT OF COVID-19 ON OUTLOOK CANNOT BE RELIABLY ASSESSED AT THIS TIME

Fresenius reports Q1 net income beat after demand for COVID-19 drugs jumps

German healthcare group Fresenius beat first-quarter net income expectations on Wednesday, citing a spike in demand for drugs and devices for COVID-19 patients in Europe and the United States and German legislation to ease the financial burden on hospitals.

EARNINGS POLL - Fresenius SE & Co KGaA quarterly results due on May 6

(All figures in EUR) * Fresenius SE & Co KGaA reports its first quarter results on May 6. * Year to date, Fresenius SE & Co KGaA shares are down 21.02%. * Below is a table of analyst estimates for quarterly and annual results based on Refinitiv data. Qtr to No. of Mean March2020...

BRIEF-Quva Pharma Voluntarily Recalling All Lots Of R.E.C.K. 50 Ml In Sodium Chloride-60 Ml Bd Syringe Made Using Ketorolac Being Recalled By Fresenius Kabi

* QUVA PHARMA- VOLUNTARILY RECALLING ALL LOTS OF R.E.C.K. 50 ML IN SODIUM CHLORIDE-60 ML BD SYRINGE MADE USING KETOROLAC BEING RECALLED BY FRESENIUS KABI Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Fresenius Postpones 2020 Annual General Meeting

* NEW DATE WILL BE SPECIFIED AND COMMUNICATED AS SOON AS RELIABLE PLANNING IS POSSIBLE

Fresenius: Coronavirus will have negative but not very significant impact on Helios

German healthcare group Fresenius on Friday said the financial impact of the coronavirus pandemic on its Helio Germany hospitals business in 2020 would be negative but not very significant if the outbreak largely subsided by the summer.

Fresenius: Staff, equipment may not suffice for coronavirus peak: WirtschaftsWoche

The chief executive of German healthcare group Fresenius told WirtschaftsWoche magazine that he could not guarantee the German healthcare group's staff and equipment would suffice for the peak of the coronavirus crisis.

Hungary cbanker Nagy flags further steps to help economy

Hungary's economy will need lots of fiscal steps as well to support a V-shaped recovery and the National Bank of Hungary also has further tools at its disposal to use later, Deputy Governor Marton Nagy said on Tuesday.

Fresenius says China drug production back to normal

German healthcare group Fresenius said its generic drugs and infusions unit Kabi had ramped up production in China back to normal levels after government-imposed coronavirus quarantine restrictions were eased.

BRIEF-Fresenius Helios Quirónsalud Hospitals In Spain Remain Fully Operational

* ALL FRESENIUS HELIOS QUIRÓNSALUD HOSPITALS IN SPAIN ARE FULLY OPERATIONAL

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up